Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b Open-Label Study of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 2 Hepatitis C Virus (HCV) and Hepatitis B Virus (HBV) Coinfection

NCT02613871 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT02613871
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02613871 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b Open-Label Study of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 2 Hepatitis C Virus (HCV) and Hepatitis B Virus (HBV) Coinfection
Lead sponsor
Gilead Sciences
Phase
Phase 3
Overall status
Completed
Start date
December 22, 2015
Completion date
November 7, 2018
Enrollment
111 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c virus infection